Biocon and Optimer Pharmaceuticals have entered into a long-term supply agreement for the commercial manufacturing of the active pharmaceutical ingredient Fidaxomicin, Optimer`s lead product candidate for the treatment of CDI.
Source :www.biginfotech.in
Source :www.biginfotech.in
No comments:
Post a Comment